NEVRO CORP's ticker is and the CUSIP is 64157FAC7. A total of 26 filers reported holding NEVRO CORP in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,457,918 | -0.4% | 1,574,000 | 0.0% | 0.00% | – |
| Q1 2023 | $1,463,820 | -37.3% | 1,574,000 | -38.9% | 0.00% | – |
| Q4 2022 | $2,335,905 | -54.8% | 2,574,000 | -53.8% | 0.00% | -100.0% |
| Q3 2022 | $5,166,000 | +0.9% | 5,574,000 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $5,118,000 | -12.8% | 5,568,000 | +0.2% | 0.00% | 0.0% |
| Q1 2022 | $5,869,000 | -5.4% | 5,557,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $6,206,000 | -30.2% | 5,557,000 | -16.0% | 0.00% | 0.0% |
| Q3 2021 | $8,891,000 | -11.7% | 6,613,000 | +13.8% | 0.00% | 0.0% |
| Q2 2021 | $10,064,000 | +52.4% | 5,811,000 | +33.5% | 0.00% | 0.0% |
| Q1 2021 | $6,605,000 | -9.1% | 4,353,000 | +8.8% | 0.00% | 0.0% |
| Q4 2020 | $7,266,000 | +52.5% | 4,000,000 | +30.3% | 0.00% | 0.0% |
| Q3 2020 | $4,765,000 | -37.5% | 3,069,000 | -44.8% | 0.00% | -50.0% |
| Q2 2020 | $7,624,000 | – | 5,556,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BRAIDWELL LP | 109,251,000 | $102,018,584 | 3.22% |
| Opti Capital Management, LP | 19,500,000 | $18,574 | 1.34% |
| Context Capital Management, LLC | 10,702 | $10,207 | 0.82% |
| PFM Health Sciences, LP | 17,500,000 | $16,341,500 | 0.77% |
| LINDEN ADVISORS LP | 21,366,000 | $19,993,448 | 0.20% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 1,595,000 | $1,543,041 | 0.03% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 6,667,000 | $6,225,645 | 0.03% |
| Rock Springs Capital Management LP | 500,000 | $472,128 | 0.01% |
| LAZARD ASSET MANAGEMENT LLC | 0 | $933 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |